SELLAS Life Sciences Group, Inc.
SLS
$7.68
-$0.30-3.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.12M | 2.43M | 2.87M | 3.00M | 2.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.25M | 7.16M | 7.08M | 6.87M | 6.06M |
| Operating Income | -9.25M | -7.16M | -7.08M | -6.87M | -6.06M |
| Income Before Tax | -8.41M | -7.66M | -6.79M | -6.60M | -5.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.41M | -7.66M | -6.79M | -6.60M | -5.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.41M | -7.66M | -6.79M | -6.60M | -5.81M |
| EBIT | -9.25M | -7.16M | -7.08M | -6.87M | -6.06M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.05 | -0.05 | -0.06 | -0.07 | -0.07 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
| EPS Diluted | -0.05 | -0.05 | -0.06 | -0.07 | -0.07 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 172.48M | 141.26M | 108.40M | 98.56M | 87.76M |
| Average Diluted Shares Outstanding | 172.48M | 141.26M | 108.40M | 98.56M | 87.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |